Monopar Therapeutics Inc. announced its financial results for the first quarter ended March 31, 2025, on May 13, 2025. The company reported $54.6 million in cash, cash equivalents, and investments as of March 31, 2025.
The net loss for the first quarter of 2025 was $2.6 million, or $0.38 per share, compared to a net loss of $1.6 million, or $0.51 per share, for the first quarter of 2024. Research and development expenses increased by $677,000 to $1,643,000, driven by higher personnel expenses and MNPR-101 clinical trial activity.
General and administrative expenses rose by $821,000 to $1,578,000, primarily due to increased Board compensation and G&A personnel expenses. Interest income increased by $515,000 due to higher cash balances from Q4 2024 financings. Monopar expects its current funds to be sufficient to continue operations at least through December 31, 2026, supporting the ALXN1840 NDA filing and radiopharmaceutical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.